Table 2.

Clinicopathologic characteristics of 44 patients with LRR

	Total (n=44)	Low RS (n=13)	Intermediate RS (n=22)	High RS (n=9)
Age at diagnosis, years
<40 years	39 (88.6%)	11 (84.6%)	2 (9.1%)	1 (11.1%)
≥40 years	5 (11.4%)	2 (15.4%)	20 (90.9%)	8 (88.9%)
Median (range)	54 (34–79)	54 (35–79)	51 (38–75)	57 (34–69)
Tumor size, median (range), cm	1.6 (0.5–3.5)	1.3 (0.5–3.5)	1.7 (0.5–3.4)	1.6 (0.6–2.6)
Multifocality/multicentricity	9 (20.5%)	6 (46.2%)	3 (13.6%)	0
LVI	17 (38.6%)	4 (30.8%)	11 (50%)	2 (22.2%)
Local Treatment
BCS	3 (6.8%)	2 (15.4%)	0	1 (11.1%)
BCS + radiation	27 (61.4%)	7 (53.8%)	14 (63.6%)	6 (66.7%)
Total mastectomy	14 (31.8%)	4 (30.8%)	8 (36.4%)	2 (22.2%)
Systemic therapy
Endocrine therapy only	16 (36.4%)	8 (61.5%)	6 (27.3%)	2 (22.2%)
Endocrine + chemotherapy	25 (56.8%)	4 (30.8%)	15 (68.2%)	6 (66.7%)
Chemotherapy only	2 (4.5%)	0	1 (4.5%)	1 (11.1%)
None	1 (2.3%)	1 (7.7%)	0	0

BCS, breast-conserving surgery; LVI, lymphovascular invasion; LRR, locoregional recurrence; RS, recurrence score.